Federation Des Caisses Desjardins Du Quebec Beam Therapeutics Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2024	SELL	$29.32 - $35.99 $586 - $719	-20 Closed	0 $0
Q1 2022 Aug 14, 2024	BUY	$53.73 - $82.16 $1,074 - $1,643	20 New	20 $1.15 Million
Q2 2021 Aug 30, 2024	BUY	$64.12 - $128.71 $1,282 - $2,574	20 New	20 $2.57 Million

Others Institutions Holding BEAM

# of Institutions

236

Shares Held

75.2M

Call Options Held

438K

Put Options Held

232K

Farallon Capital Management LLC San Francisco, CA

8.21M
Shares

$208 Million
1.01% of portfolio
Vanguard Group Inc Valley Forge, PA

7.84M
Shares

$198 Million
0.0% of portfolio
Black Rock Inc. New York, NY

7.63M
Shares

$193 Million
0.0% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

6.53M
Shares

$165 Million
1.52% of portfolio
Arch Venture Management, LLC Chicago, IL

4.83M
Shares

$122 Million
71.21% of portfolio

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account